KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $444.1 million.

  • Halozyme Therapeutics' Net Income towards Common Stockholders rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Net Income towards Common Stockholders of $444.1 million as of FY2024, which was up 57.71% from $281.6 million recorded in FY2023.
  • Halozyme Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $444.1 million during FY2024, with a 5-year trough of $129.1 million in FY2020.
  • In the last 3 years, Halozyme Therapeutics' Net Income towards Common Stockholders had a median value of $281.6 million in 2023 and averaged $309.3 million.
  • In the last 5 years, Halozyme Therapeutics' Net Income towards Common Stockholders surged by 278.69% in 2020 and then plummeted by 49.81% in 2022.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Net Income towards Common Stockholders stood at $129.1 million in 2020, then soared by 211.97% to $402.7 million in 2021, then slumped by 49.81% to $202.1 million in 2022, then surged by 39.31% to $281.6 million in 2023, then soared by 57.71% to $444.1 million in 2024.